Tags

Type your tag names separated by a space and hit enter

Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study.
Eur J Gastroenterol Hepatol 2007; 19(12):1097-103EJ

Abstract

AIM

To assess the proportion of physician-diagnosed irritable bowel syndrome (IBS) patients who conform to Rome II criteria, and evaluate the impact of IBS on quality of life (QoL) and costs in France.

METHODS

This cross-sectional study collected information retrospectively from the preceding year. Physicians (randomly selected) enrolled their first four IBS patients during the study period. Patients were classified (secondarily) according to Rome II criteria. IBS-related costs during the previous year were estimated.

RESULTS

Of the 452 physician-diagnosed IBS patients (mean age 53.9+/-14.9 years; 75.4% women), 23% did not meet the diagnostic criteria; 36.5% met all diagnostic criteria, and 32% experienced severe or very severe abdominal pain/discomfort (Subjects' Global Assessment of relief). IBS patients had lower QoL (SF-36 scale) than the general French population, and Rome II patients had the lowest QoL. Most prescriptions treated abdominal pain (72%) and bloating (58%). Approximately 8% of patients had been hospitalized due to IBS during the preceding year. The average total annual direct cost/patient was 756 euro.

CONCLUSIONS

These data confirm that IBS involves large direct medical costs in France, and that IBS patients experience lower QoL than the general population. A small and not significant economic difference between the Rome II and non-Rome II IBS patient groups was observed.

Authors+Show Affiliations

Novartis Pharma, Rueil Malmaison, Bourg la Reine, France.

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

17998835

Citation

Brun-Strang, Catherine, et al. "Irritable Bowel Syndrome in France: Quality of Life, Medical Management, and Costs: the Encoli Study." European Journal of Gastroenterology & Hepatology, vol. 19, no. 12, 2007, pp. 1097-103.
Brun-Strang C, Dapoigny M, Lafuma A, et al. Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study. Eur J Gastroenterol Hepatol. 2007;19(12):1097-103.
Brun-Strang, C., Dapoigny, M., Lafuma, A., Wainsten, J. P., & Fagnani, F. (2007). Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study. European Journal of Gastroenterology & Hepatology, 19(12), pp. 1097-103.
Brun-Strang C, et al. Irritable Bowel Syndrome in France: Quality of Life, Medical Management, and Costs: the Encoli Study. Eur J Gastroenterol Hepatol. 2007;19(12):1097-103. PubMed PMID: 17998835.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study. AU - Brun-Strang,Catherine, AU - Dapoigny,Michel, AU - Lafuma,Antoine, AU - Wainsten,Jean Pierre, AU - Fagnani,Francis, PY - 2007/11/14/pubmed PY - 2008/2/29/medline PY - 2007/11/14/entrez SP - 1097 EP - 103 JF - European journal of gastroenterology & hepatology JO - Eur J Gastroenterol Hepatol VL - 19 IS - 12 N2 - AIM: To assess the proportion of physician-diagnosed irritable bowel syndrome (IBS) patients who conform to Rome II criteria, and evaluate the impact of IBS on quality of life (QoL) and costs in France. METHODS: This cross-sectional study collected information retrospectively from the preceding year. Physicians (randomly selected) enrolled their first four IBS patients during the study period. Patients were classified (secondarily) according to Rome II criteria. IBS-related costs during the previous year were estimated. RESULTS: Of the 452 physician-diagnosed IBS patients (mean age 53.9+/-14.9 years; 75.4% women), 23% did not meet the diagnostic criteria; 36.5% met all diagnostic criteria, and 32% experienced severe or very severe abdominal pain/discomfort (Subjects' Global Assessment of relief). IBS patients had lower QoL (SF-36 scale) than the general French population, and Rome II patients had the lowest QoL. Most prescriptions treated abdominal pain (72%) and bloating (58%). Approximately 8% of patients had been hospitalized due to IBS during the preceding year. The average total annual direct cost/patient was 756 euro. CONCLUSIONS: These data confirm that IBS involves large direct medical costs in France, and that IBS patients experience lower QoL than the general population. A small and not significant economic difference between the Rome II and non-Rome II IBS patient groups was observed. SN - 0954-691X UR - https://www.unboundmedicine.com/medline/citation/17998835/Irritable_bowel_syndrome_in_France:_quality_of_life_medical_management_and_costs:_the_Encoli_study_ L2 - http://Insights.ovid.com/pubmed?pmid=17998835 DB - PRIME DP - Unbound Medicine ER -